At that point, the question feels reasonable. But for most early-stage health startups, it is usually the wrong one. The better question is much more practical:

What decision are we trying to make next, and what evidence would actually help us make it?

Many founders jump straight to “we need to do more research” when the more useful move is figuring out what kind of evidence would help the business move forward. That distinction matters more than most people realize.

For an early-stage company, the goal should rarely be to do the most rigorous work possible. Instead, the goal should be to build early-stage health startup evidence that helps the business move. That is what a real science strategy for founders looks like. It is not about doing research for the sake of looking credible. It is about identifying the right evidence that will help the company make better decisions and move forward with more confidence.

Why This Question Sends Founders Off Course

When founders ask, “Do we really need science?”, they are usually not rejecting the idea of evidence. More often, they are reacting to uncertainty about what kind of evidence would actually help the business move forward. The product may be promising, but adoption is uneven. Buyers may like the story, but want more proof. The team knows credibility matters, but is not sure what kind of evidence would actually strengthen the next conversation.

That uncertainty is real. But it does not automatically mean the next move should be conducting a study or commissioning more research.

This is where early-stage teams consistently lose time. Instead of defining the decision they need to make, they jump straight to methods. They start talking about validation, assume they need a pilot, or look for something that sounds more rigorous. In other words, they start asking, “Do startups need more research?” before they have defined what the evidence is supposed to do.

That question is usually too vague to be useful. It pushes founders toward scientific activity before they have clarified what business risk they are trying to reduce. Once that happens, it becomes much easier to spend time and money on work that feels responsible but does not actually improve the product, strengthen the positioning, or make the commercial story more credible.

Why More Research May Be the Wrong Next Step

This matters even more in the current market because the bar for credibility has changed.

For example, purchasers are not just looking for digital health solutions that are engaging or innovative. They are increasingly looking for evidence that a solution can improve outcomes and justify investment. 

Peterson Health Technology Institute’s 2025 State of Digital Health Purchasing survey found that the market is maturing, with purchasers demanding proof of measurable clinical and economic outcomes, not just engagement metrics. In the same survey, 84% of purchasers said digital health tools can improve health outcomes, and 68% said they can reduce costs. But that does not mean every solution earns trust automatically. Respondents also pointed to poor clinical outcomes, weak engagement, and limited integration as common reasons tools fall short.

The broader industry view points in the same direction. IQVIA’s Digital Health Trends 2025 report notes that digital health is entering a new phase as stakeholders refine evidence standards, reimbursement pathways, and business models. This is not a market that rewards “more research” for its own sake. It rewards evidence that is decision-aligned, useful, and credible for the people making adoption, reimbursement, and purchasing decisions.

That does not mean every founder needs a large or formal study. If anything, it points in the opposite direction. In a more scrutinized market, founders need evidence that is decision-aligned and clearly connected to the next business milestone. That is very different from simply doing more research.

What Early-Stage Health Startups Usually Need First

Most early-stage health startups do not start by needing a big outcomes story. They start by needing a strategy that yields clarity.

They need to know whether people can actually use the product without friction, whether the value is clear quickly enough to support retention, whether the product fits into real life or workflow the way the team assumes, and whether users or buyers are hesitating because the product is weak or because the credibility story is incomplete.

Those questions are often more important than jumping straight to long-term outcome claims.

This is where founders often overreach. They assume the next step is to prove impact, when the more urgent need is often to understand feasibility, usability, or fit.

That is the issue many founders miss. The question is not whether science matters. It does, full stop. The question is what level of evidence is appropriate for the decision in front of you.

You May Already Have More Evidence Than You Think

Another reason founders default to the wrong question is that they assume science starts with something new. Sometimes it does. But many early-stage teams already have useful evidence inside the business. It is just not organized yet.

It may be sitting in onboarding behavior, drop-off patterns, customer interviews, support tickets, pilot feedback, repeated objections in sales conversations, or usage patterns that point to where the value is actually landing.

That does not mean those signals are enough forever. But it does mean most startups are not starting from zero. They are starting from unstructured evidence.

That is a meaningful difference. If you are already seeing the same friction points, the same objections, the same drop-off moments, or the same moments where users clearly understand the value, that is not just noise. It is often the first layer of evidence that should shape what you test next.

One of the biggest mistakes early-stage teams make is overlooking what the business is already telling them because they assume “real evidence” has to look formal. It does not, especially at the beginning.

A Better Question for Early-Stage Founders

If you are an early-stage founder, a better question is this:

What evidence would reduce the most important business risk right now?

That question usually makes the next move much clearer.

Sometimes the answer is a small feasibility test. Sometimes it is structured customer interviews. Sometimes it is a survey using validated questions. Sometimes it is a tighter analysis of the data you already have. Sometimes it is simply narrowing the claim so you stop promising more than the evidence can support.

But it almost always leads to a better next step than asking “do we really need science?”

Asking whether you need science is not a strategy. A real science strategy for founders starts with the business decision, the uncertainty behind it, and the evidence most likely to reduce that uncertainty. That is what helps founders build credibility without creating drag.

If This Question Feels Familiar

This is exactly why we created the Science Strategy for Early-Stage Founders Masterclass.

It is built for founders who know evidence matters, but need a more practical way to decide what to test now, what can wait, what evidence is actually useful at their stage, and how to build credibility without overbuilding too early.

The goal is not to turn founders into researchers. The goal is to help you understand how to use science to make smarter business decisions, faster. If you are asking whether you need more research, there is a good chance the better question is what kind of evidence would actually help move the business forward. That is the problem the Masterclass is designed to solve.

Frequently Asked Questions

Do early-stage health startups need more research before fundraising?

Not always. Many early-stage investors are not looking for a large formal study. More often, they want evidence that the founder understands what is uncertain, is testing the right things, and is learning in a disciplined way.

What kind of evidence should an early-stage health startup prioritize first?

Usually the evidence that reduces the biggest immediate business risk. That often includes feasibility, usability, early behavior patterns, product fit, or signals that clarify why users stay, leave, or hesitate.

What is the difference between more research and the right evidence?

More research is activity. The right evidence helps you make a better decision. It changes what you build, what you say, what you test next, or how you go to market.

How do I know if I am doing the wrong research too early?

A simple filter is whether the results would clearly change what happens next. If the work feels disproportionate to your stage, or would not materially affect a real business decision, it may not be the right priority yet.